BACKGROUND AND PURPOSE: Conditioned gaping reactions reflect nausea-induced behaviour in rats. Cannabinoid 1 receptor (CB(1) ) agonists interfere with the establishment of nausea-induced conditioned gaping; however, it is not known if their effects are mediated by an action at peripheral or central CB(1) receptors. EXPERIMENTAL APPROACH: We utilized the conditioned gaping model of nausea to evaluate the effect of peripheral and central administration of the peripherally restricted CB(1) agonist, CB13, on the establishment of LiCl-induced gaping in rats. We further evaluated the ability of HU-210 administered to the gustatory insular cortex (GIC) or visceral insular cortex (VIC) to interfere with LiCl-induced conditioned gaping and determined if this effect was mediated by CB(1) receptors. KEY RESULTS: Central, but not peripheral, CB13 suppressed LiCl-induced conditioned gaping. Central administration of the potent CB(1) agonist, HU-210, delivered to the VIC, but not the GIC, suppressed the establishment of LiCl-induced gaping reactions, but not LiCl-induced suppression of hedonic reactions or conditioned taste avoidance. This pattern of results suggests that HU-210 delivered to the VIC prevented LiCl-induced nausea, but not learning per se. The suppression of LiCl-induced conditioned gaping by HU-210 was mediated by CB(1) receptors because it was prevented by co-administration of CB(1) antagonist/inverse agonist, AM-251, into the VIC. A high dose of AM-251 (20 µg) administered alone into the VIC did not produce conditioned gaping reactions. CONCLUSIONS AND IMPLICATIONS: The nausea-relieving effects of CB(1) agonists, but not the nausea-inducing effects of CB(1) inverse agonists, are mediated, at least in part, by their action at the VIC in rats.
BACKGROUND AND PURPOSE: Conditioned gaping reactions reflect nausea-induced behaviour in rats. Cannabinoid 1 receptor (CB(1) ) agonists interfere with the establishment of nausea-induced conditioned gaping; however, it is not known if their effects are mediated by an action at peripheral or central CB(1) receptors. EXPERIMENTAL APPROACH: We utilized the conditioned gaping model of nausea to evaluate the effect of peripheral and central administration of the peripherally restricted CB(1) agonist, CB13, on the establishment of LiCl-induced gaping in rats. We further evaluated the ability of HU-210 administered to the gustatory insular cortex (GIC) or visceral insular cortex (VIC) to interfere with LiCl-induced conditioned gaping and determined if this effect was mediated by CB(1) receptors. KEY RESULTS: Central, but not peripheral, CB13 suppressed LiCl-induced conditioned gaping. Central administration of the potent CB(1) agonist, HU-210, delivered to the VIC, but not the GIC, suppressed the establishment of LiCl-induced gaping reactions, but not LiCl-induced suppression of hedonic reactions or conditioned taste avoidance. This pattern of results suggests that HU-210 delivered to the VIC prevented LiCl-induced nausea, but not learning per se. The suppression of LiCl-induced conditioned gaping by HU-210 was mediated by CB(1) receptors because it was prevented by co-administration of CB(1) antagonist/inverse agonist, AM-251, into the VIC. A high dose of AM-251 (20 µg) administered alone into the VIC did not produce conditioned gaping reactions. CONCLUSIONS AND IMPLICATIONS: The nausea-relieving effects of CB(1) agonists, but not the nausea-inducing effects of CB(1) inverse agonists, are mediated, at least in part, by their action at the VIC in rats.
Authors: N L Cluny; V K Vemuri; A P Chambers; C L Limebeer; H Bedard; J T Wood; B Lutz; A Zimmer; L A Parker; A Makriyannis; K A Sharkey Journal: Br J Pharmacol Date: 2010-10 Impact factor: 8.739
Authors: Kelly S Sink; Peter J McLaughlin; Jodi Anne T Wood; Cara Brown; Pusheng Fan; V Kiran Vemuri; Yan Peng; Yan Pang; Teresa Olszewska; Teresa Olzewska; Ganesh A Thakur; Alex Makriyannis; Linda A Parker; John D Salamone Journal: Neuropsychopharmacology Date: 2007-06-20 Impact factor: 7.853
Authors: C L Limebeer; V K Vemuri; H Bedard; S T Lang; K P Ossenkopp; A Makriyannis; L A Parker Journal: Br J Pharmacol Date: 2010-09 Impact factor: 8.739
Authors: Cheryl L Limebeer; Erin M Rock; Nirushan Puvanenthirarajah; Micah J Niphakis; Benjamin F Cravatt; Linda A Parker Journal: Behav Neurosci Date: 2016-04 Impact factor: 1.912
Authors: Linda A Parker; Micah J Niphakis; Rachel Downey; Cheryl L Limebeer; Erin M Rock; Martin A Sticht; Heather Morris; Rehab A Abdullah; Aron H Lichtman; Benjamin F Cravatt Journal: Psychopharmacology (Berl) Date: 2014-08-03 Impact factor: 4.530
Authors: Kiri L Wills; Gavin N Petrie; Geneva Millett; Cheryl L Limebeer; Erin M Rock; Micah J Niphakis; Benjamin F Cravatt; Linda A Parker Journal: Neuropsychopharmacology Date: 2015-12-09 Impact factor: 7.853
Authors: Martin A Sticht; Cheryl L Limebeer; Benjamin R Rafla; Rehab A Abdullah; Justin L Poklis; Winnie Ho; Micah J Niphakis; Benjamin F Cravatt; Keith A Sharkey; Aron H Lichtman; Linda A Parker Journal: Neuropharmacology Date: 2015-11-02 Impact factor: 5.250
Authors: Linda A Parker; Cheryl L Limebeer; Erin M Rock; Martin A Sticht; Jordan Ward; Greig Turvey; Othman Benchama; Girija Rajarshi; JodiAnne T Wood; Shakiru O Alapafuja; Alexandros Makriyannis Journal: Psychopharmacology (Berl) Date: 2016-04-06 Impact factor: 4.530